Description
Imbrofitol Tablets №36
Composition
Imbrofitol tablets №36 contain the active ingredient X along with inactive ingredients Y.
Mechanism of Action
The pharmacological effects of Imbrofitol tablets №36 are mediated through mechanism X, which selectively targets specific receptors in the body, resulting in therapeutic outcomes. This targeted mechanism not only reduces the incidence of side effects but also enhances the overall efficacy of the medication.
Pharmacological Properties
The active ingredient in Imbrofitol tablets №36 exhibits [describe specific pharmacological properties such as receptor affinity, enzyme inhibition, or physiological effects]. These properties contribute to the therapeutic actions of the medication.
Indications for Use
Imbrofitol tablets №36 are indicated for the treatment of condition A and condition B. It is prescribed for [mention any other specific indications supported by clinical evidence].
Contraindications
Avoid taking Imbrofitol tablets №36 if you have a known allergy to any of the active or inactive ingredients present in the formulation. Additionally, individuals with condition C should consult their healthcare provider before initiating treatment with this medication to prevent any potential adverse reactions.
Side Effects
Common side effects associated with Imbrofitol tablets №36 may include [list common side effects here]. Patients are advised to promptly seek medical advice if they experience persistent or worsening side effects while using this medication.
Usage Instructions
Patients should take Imbrofitol tablets №36 exactly as prescribed by their healthcare provider. The typical dosage regimen involves taking X tablets daily. To minimize the risk of gastrointestinal discomfort, it is recommended to administer the tablets with food. The tablets should be swallowed whole with an ample amount of water.
Benefits Compared to Analogues
Clinical trials comparing Imbrofitol tablets №36 with similar pharmacotherapies have demonstrated either non-inferiority or superiority in terms of both efficacy and safety profiles. Patients receiving Imbrofitol exhibited a lower incidence of adverse events compared to alternative treatments, such as Drug Y (Source: Clinical Trial XYZ).
Suitable Patient Groups
Imbrofitol tablets №36 are suitable for [mention suitable patient groups, e.g., adults, elderly, not recommended for children under 12 years old]. The medication is well-tolerated in [specific patient populations like those with comorbidities or specific demographic characteristics].
Storage and Shelf Life
It is advised to store Imbrofitol tablets №36 in a cool and dry location, shielded from direct sunlight. Patients should adhere to the expiration date indicated on the packaging and refrain from using the tablets beyond this date to ensure optimal efficacy and safety.
Packaging Description
Imbrofitol tablets №36 are meticulously packaged in [describe packaging details, e.g., blister packs containing 10 tablets each]. The packaging is designed to maintain the stability and integrity of the tablets throughout their shelf life.
Clinical Evidence and Proven Effectiveness
Scientific investigations have established the substantial therapeutic benefits of the active ingredient in Imbrofitol tablets №36 for managing condition A. Notably, a study published in the Journal of Clinical Research reported a XX% improvement in symptomatic relief compared to a placebo, underscoring the medication’s efficacy in real-world clinical settings.
